Autologous Stem Cell Transplantation for Crohn's Disease
Part of paid clinical trials in Pittsburgh, Pennsylvania.
- Sponsor
- Paul Szabolcs
- Study ID
- NCT00692939
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 10 Years - 60 Years
- Healthy Volunteers
- Not accepted
Interventions
- autologous CD34-selected peripheral blood stem cells transplant — BIOLOGICALhigh-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
- Alemtuzumab — DRUGTransplant conditioning
- ATG — DRUGTransplant conditioning
- Melphalan — DRUGTransplant conditioning
- Thiotepa — DRUGTransplant conditioning
- Rituximab — DRUGTransplant conditioning
- Cyclophosphamide — DRUGMobilization
- G-CSF — DRUGMobilization
- Mesna — DRUGMobilization
Study Details
The objective of this study is to evaluate the safety and effectiveness of administering high-dose chemotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC) in pediatric and adult patients with severe Crohn's disease.
Key Dates
- Start date
- Jun 26, 2012
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2026
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: 1High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
Primary Outcome Measure
Number of participants with regimen-related toxicities. [ Time Frame: From baseline to 24 months post bone marrow transplant ]
Central Contacts
- Shawna H McIntyre, RN412-692-5552
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team | Pittsburgh | Pennsylvania | 15224 | Paul Szabolcs, MD (PRINCIPAL_INVESTIGATOR) |
| UPMC Prebyterian- Adult Gastroenterology | Pittsburgh | Pennsylvania | 15213 |
Find similar trials in Pittsburgh, PA
By condition
Related Studies
- Fecal Microbiome TransplantPHASE1 · Enrolling By Invitation · Judith Kelsen · Philadelphia, Pennsylvania
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)PHASE3 · Recruiting · Eli Lilly and Company · San Francisco, California
- A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)PHASE3 · Recruiting · Takeda · Mobile, Alabama